Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Hematologic Malignancies”

3,490 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 3,490 results

Early research (Phase 1)Looking for participantsNCT06708897
What this trial is testing

Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Who this might be right for
CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)+2 more
Lomond Therapeutics Holdings, Inc. 84
Testing effectiveness (Phase 2)Study completedNCT00040846
What this trial is testing

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+97 more
Fred Hutchinson Cancer Center 60
Large-scale testing (Phase 3)UnknownNCT00003603
What this trial is testing

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Riverside Haematology Group 660
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Early research (Phase 1)Looking for participantsNCT07586618
What this trial is testing

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

Who this might be right for
Lymphoblastic LymphomaAcute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc 24
Not applicableLooking for participantsNCT07234110
What this trial is testing

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Who this might be right for
Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China 18
Early research (Phase 1)Study completedNCT00058396
What this trial is testing

Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)UnknownNCT03598179
What this trial is testing

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Who this might be right for
Lymphoma, B-CellLeukemia, B-cell
The First Affiliated Hospital with Nanjing Medical University 10
Early research (Phase 1)Looking for participantsNCT07239323
What this trial is testing

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Who this might be right for
B-Acute Lymphoblastic LeukemiaB Cell Non-Hodgkin's LymphomaMultiple Myeloma
Chongqing Precision Biotech Co., Ltd 24
Testing effectiveness (Phase 2)Looking for participantsNCT04588922
What this trial is testing

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Who this might be right for
Hematologic Malignancies
Sellas Life Sciences Group 160
Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Early research (Phase 1)Ended earlyNCT03486067
What this trial is testing

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 183
Early research (Phase 1)Ended earlyNCT03922477
What this trial is testing

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Hoffmann-La Roche 13
Testing effectiveness (Phase 2)Study completedNCT01720875
What this trial is testing

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Who this might be right for
Multiple Myeloma
University of Leeds 16
Testing effectiveness (Phase 2)Ended earlyNCT02294357
What this trial is testing

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Early research (Phase 1)UnknownNCT04984434
What this trial is testing

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD 68
Early research (Phase 1)Study completedNCT00900809
What this trial is testing

QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
ImmunityBio, Inc. 7
Early research (Phase 1)Ended earlyNCT00928200
What this trial is testing

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Who this might be right for
Relapsed Acute Lymphoblastic LeukemiaAllergy to PEG e.Coli AsparaginaseAllergy to Native e.Coli Asparaginase
Therapeutic Advances in Childhood Leukemia Consortium 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT03573700
What this trial is testing

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, Refractory
St. Jude Children's Research Hospital 24
Early research (Phase 1)Study completedNCT03111992
What this trial is testing

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 26
Next Page